Cardiovascular & hematological agents in medicinal chemistry
-
Cardiovasc Hematol Agents Med Chem · Jan 2016
Observational StudyTapentadol PR for pain syndromes in real life patients with hematological malignancy.
More than 50% of oncohematological patients suffer from pain syndrome, mostly originating from the bone, which often include nociceptive and neuropathic complaints. Tapentadol, a recently available treatment option for cancer pain, exerts a dual analgesic mechanisms (opioid and noradrenergic), allowing for a high clinical efficacy as well as for a reduction in adverse events compared to traditional opioids. ⋯ In oncohematological patients on pain, tapentadol PR was effective and well tolerated, so representing a suitable treatment option in this difficult setting.